For research use only. Not for therapeutic Use.
LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression[1][2].
LJ001 (0.782- 200 μM; 24 h) shows no significant cytotoxicity with a CC50 value of 146.4 μM for ST cells[1].
LJ001 (12.5 µM; 12, 24 h) inhibits transmissible gastroenteritis virus (TGEV) and porcine deltacoronavirus (PDCoV) infection[1].
LJ001 (12.5 µM; 1, 6,12, 24 h) decreases the TGEV and PDCoV gene mRNA expression in ST cells[1].
LJ001 can inhibit the entry and spread of some enveloped viruses, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza, Ebola, arenaviruses and poxvi ruses[1].
LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) shows no toxicity in mouse[2].
| Catalog Number | I030883 |
| CAS Number | 851305-26-5 |
| Synonyms | (5Z)-5-[(5-phenylfuran-2-yl)methylidene]-3-prop-2-enyl-2-sulfanylidene-1,3-thiazolidin-4-one |
| Molecular Formula | C17H13NO2S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H13NO2S2/c1-2-10-18-16(19)15(22-17(18)21)11-13-8-9-14(20-13)12-6-4-3-5-7-12/h2-9,11H,1,10H2/b15-11- |
| InChIKey | YAIFLEPRFXXIFQ-PTNGSMBKSA-N |
| SMILES | C=CCN1C(=O)C(=CC2=CC=C(O2)C3=CC=CC=C3)SC1=S |
| Reference | [1]. Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167. [2]. Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3157-62. |
